James Markert, MD
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| A Phase IB 2 Dose Trial of IRS-1 HSV C134 (IND 17296) Administered Intratumorally in Patients With Recurrent Malignant Glioma (NCT06614855) | James Markert, MD | 2025-06-02 |
Track James Markert, MD automatically
Every clearance here is in the API, with alerts when new ones post.